세계의 심장 아밀로이드증 시장 보고서(2025년)

Cardiac amyloidosis is a condition characterized by the deposition of abnormal amyloid proteins in the heart tissue, resulting in stiffness and impaired function. This leads to heart failure, arrhythmias, and other cardiovascular complications. Early diagnosis and treatment are essential for managing symptoms and slowing disease progression.

The primary types of cardiac amyloidosis are light-chain amyloidosis and transthyretin amyloidosis. Light-chain amyloidosis (AL amyloidosis) is a disorder in which misfolded immunoglobulin light chains form amyloid deposits in various organs, including the heart, causing dysfunction and potential organ failure. Treatment options include chemotherapy, surgery, supportive care, stem cell transplantation, and targeted therapy. The disease is primarily managed in hospitals, ambulatory surgical centers, and clinics.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The cardiac amyloidosis market research report is one of a series of new reports from The Business Research Company that provides cardiac amyloidosis market statistics, including the cardiac amyloidosis industry global market size, regional shares, competitors with the cardiac amyloidosis market share, detailed cardiac amyloidosis market segments, market trends, and opportunities, and any further data you may need to thrive in the cardiac amyloidosis industry. This cardiac amyloidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cardiac amyloidosis market size has grown strongly in recent years. It will grow from $5.26 billion in 2024 to $5.73 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to rising prevalence of amyloidosis-related conditions, rising prevalence of genetic mutations, increasing awareness, increasing prevalence of transthyretin amyloidosis cases, and rising geriatric population.

The cardiac amyloidosis market size is expected to see strong growth in the next few years. It will grow to $8.03 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to increasing diagnosis rates, government support and initiatives, increased diagnosis rates, rising prevalence of genetic mutations, and patient assistance programs. Major trends in the forecast period include development of new therapies such as vulrisiran, expanding research in gene therapy, a focus on precision medicine, advancements in diagnostic technologies, and the development of novel therapies.

The forecast of 8.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. rare disease care by inflating prices of transthyretin(TTR) stabilizers and cardiac Magnetic Resonance Imaging(MRI) contrast agents developed in Switzerland and Japan, resulting in delayed diagnosis and higher specialty treatment expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising geriatric population is expected to drive the growth of the cardiac amyloidosis market in the coming years. The geriatric population refers to individuals aged 65 and older who often require specialized healthcare due to age-related conditions. The steady increase in this population is driven by rising life expectancy, advancements in medical care, and declining birth rates. Since aging is a significant risk factor for amyloid protein accumulation in the heart, the growing number of older adults contributes to the increasing prevalence of cardiac amyloidosis. For example, according to the Population Reference Bureau, a US-based nonprofit organization, the US population aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. As a result, the expanding geriatric demographic is expected to fuel the growth of the cardiac amyloidosis market.

Leading companies in the cardiac amyloidosis market are focusing on technological advancements, such as artificial intelligence (AI)-based diagnostic tools, to improve early disease detection and enhance clinical outcomes. AI-powered, software-only medical devices can analyze echocardiographic images and identify signs of cardiac amyloidosis without the need for additional hardware or extensive clinical data. For instance, in November 2024, Ultromics Ltd., a UK-based health technology company, secured FDA clearance for EchoGo Amyloidosis, an AI-driven clinical tool for early cardiac amyloidosis detection. It is the first device in the FDA's Total Product Lifecycle Advisory Program (TAP) to receive marketing authorization. Using AI, EchoGo Amyloidosis analyzes echocardiograms from a single clip, enabling earlier detection before the disease progresses undetected.

In January 2024, Ultromics Ltd. partnered with Pfizer Inc. to further develop its Echo AI algorithm for cardiac amyloidosis detection. This partnership aims to enhance diagnostic accuracy and improve patient outcomes. Pfizer Inc. is a US-based pharmaceutical company specializing in innovative medicines, including treatments for cardiac amyloidosis, as well as consumer healthcare products.

Major players in the cardiac amyloidosis market are Pfizer Inc., Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Alexion Pharmaceuticals Inc., Dr. Reddy's Laboratories, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., BridgeBio Pharma Inc., Prothena Corp, Intellia Therapeutics Inc., Amylyx Pharmaceuticals, Neurimmune AG, SOM Biotech, Oncopeptides, Attralus Inc., and Eidos Therapeutics.

North America was the largest region in the cardiac amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cardiac amyloidosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cardiac amyloidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cardiac amyloidosis market consists of revenues earned by entities by providing services such as early diagnosis through imaging and biomarker testing, medication management, and supportive therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiac amyloidosis market also includes sales of diagnostic imaging tools, biomarker testing kits, and disease-modifying therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cardiac Amyloidosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cardiac amyloidosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cardiac amyloidosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cardiac amyloidosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Light Chain Amyloidosis; Transthyretin Amyloidosis
• 2) By Treatment: Chemotherapy; Surgery; Supportive Care; Stem Cell Transplant; Targeted Therapy
• 3) By End-User: Hospitals; Ambulatory Surgical Centres; Clinics
• Subsegments:
• 1) By Light Chain Amyloidosis: Immunoglobulin Light Chain (AL) Amyloidosis; Primary Light Chain Amyloidosis; Secondary Light Chain Amyloidosis
• 2) By Transthyretin Amyloidosis: Hereditary Transthyretin Amyloidosis (ATTRm); Wild-type Transthyretin Amyloidosis (ATTRwt)
• Companies Mentioned: Pfizer Inc.; Sanofi S.A.; AstraZeneca plc; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Novo Nordisk A/S; Alexion Pharmaceuticals Inc.; Dr. Reddy's Laboratories; Alnylam Pharmaceuticals Inc.; Ionis Pharmaceuticals Inc.; Akcea Therapeutics Inc.; BridgeBio Pharma Inc.; Prothena Corp; Intellia Therapeutics Inc.; Amylyx Pharmaceuticals; Neurimmune AG; SOM Biotech; Oncopeptides; Attralus Inc.; Eidos Therapeutics.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cardiac Amyloidosis Market Characteristics

3. Cardiac Amyloidosis Market Trends And Strategies

4. Cardiac Amyloidosis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Cardiac Amyloidosis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cardiac Amyloidosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cardiac Amyloidosis Market Growth Rate Analysis
• 5.4. Global Cardiac Amyloidosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cardiac Amyloidosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cardiac Amyloidosis Total Addressable Market (TAM)

6. Cardiac Amyloidosis Market Segmentation

• 6.1. Global Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Light Chain Amyloidosis
• Transthyretin Amyloidosis
• 6.2. Global Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Surgery
• Supportive Care
• Stem Cell Transplant
• Targeted Therapy
• 6.3. Global Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Surgical Centres
• Clinics
• 6.4. Global Cardiac Amyloidosis Market, Sub-Segmentation Of Light Chain Amyloidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunoglobulin Light Chain (AL) Amyloidosis
• Primary Light Chain Amyloidosis
• Secondary Light Chain Amyloidosis
• 6.5. Global Cardiac Amyloidosis Market, Sub-Segmentation Of Transthyretin Amyloidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hereditary Transthyretin Amyloidosis (ATTRm)
• Wild-type Transthyretin Amyloidosis (ATTRwt)

7. Cardiac Amyloidosis Market Regional And Country Analysis

• 7.1. Global Cardiac Amyloidosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cardiac Amyloidosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cardiac Amyloidosis Market

• 8.1. Asia-Pacific Cardiac Amyloidosis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cardiac Amyloidosis Market

• 9.1. China Cardiac Amyloidosis Market Overview
• 9.2. China Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cardiac Amyloidosis Market

• 10.1. India Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cardiac Amyloidosis Market

• 11.1. Japan Cardiac Amyloidosis Market Overview
• 11.2. Japan Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cardiac Amyloidosis Market

• 12.1. Australia Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cardiac Amyloidosis Market

• 13.1. Indonesia Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cardiac Amyloidosis Market

• 14.1. South Korea Cardiac Amyloidosis Market Overview
• 14.2. South Korea Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cardiac Amyloidosis Market

• 15.1. Western Europe Cardiac Amyloidosis Market Overview
• 15.2. Western Europe Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cardiac Amyloidosis Market

• 16.1. UK Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cardiac Amyloidosis Market

• 17.1. Germany Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cardiac Amyloidosis Market

• 18.1. France Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cardiac Amyloidosis Market

• 19.1. Italy Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cardiac Amyloidosis Market

• 20.1. Spain Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cardiac Amyloidosis Market

• 21.1. Eastern Europe Cardiac Amyloidosis Market Overview
• 21.2. Eastern Europe Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cardiac Amyloidosis Market

• 22.1. Russia Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cardiac Amyloidosis Market

• 23.1. North America Cardiac Amyloidosis Market Overview
• 23.2. North America Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cardiac Amyloidosis Market

• 24.1. USA Cardiac Amyloidosis Market Overview
• 24.2. USA Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cardiac Amyloidosis Market

• 25.1. Canada Cardiac Amyloidosis Market Overview
• 25.2. Canada Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cardiac Amyloidosis Market

• 26.1. South America Cardiac Amyloidosis Market Overview
• 26.2. South America Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cardiac Amyloidosis Market

• 27.1. Brazil Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cardiac Amyloidosis Market

• 28.1. Middle East Cardiac Amyloidosis Market Overview
• 28.2. Middle East Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cardiac Amyloidosis Market

• 29.1. Africa Cardiac Amyloidosis Market Overview
• 29.2. Africa Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cardiac Amyloidosis Market Competitive Landscape And Company Profiles

• 30.1. Cardiac Amyloidosis Market Competitive Landscape
• 30.2. Cardiac Amyloidosis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Cardiac Amyloidosis Market Other Major And Innovative Companies

• 31.1. Novo Nordisk A/S
• 31.2. Alexion Pharmaceuticals Inc.
• 31.3. Dr. Reddy's Laboratories
• 31.4. Alnylam Pharmaceuticals Inc.
• 31.5. Ionis Pharmaceuticals Inc.
• 31.6. Akcea Therapeutics Inc.
• 31.7. BridgeBio Pharma Inc.
• 31.8. Prothena Corp
• 31.9. Intellia Therapeutics Inc.
• 31.10. Amylyx Pharmaceuticals
• 31.11. Neurimmune AG
• 31.12. SOM Biotech
• 31.13. Oncopeptides
• 31.14. Attralus Inc.
• 31.15. Eidos Therapeutics

32. Global Cardiac Amyloidosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cardiac Amyloidosis Market

34. Recent Developments In The Cardiac Amyloidosis Market

35. Cardiac Amyloidosis Market High Potential Countries, Segments and Strategies

• 35.1 Cardiac Amyloidosis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cardiac Amyloidosis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cardiac Amyloidosis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer